Phase II study of Taxotere (docetaxel) + ZD1839 (IRESSA) in previously untreated elderly patients (greater than or equal to 70 years old) with stage III-b (with malignant pleural effusion [MPE+]) or stage IV non-small cell lung cancer (NSCLC).

Trial Profile

Phase II study of Taxotere (docetaxel) + ZD1839 (IRESSA) in previously untreated elderly patients (greater than or equal to 70 years old) with stage III-b (with malignant pleural effusion [MPE+]) or stage IV non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 25 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top